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Reply to the comment of Wilbrink et al. on
Retrospective analysis of liraglutide and basal
insulin combination therapy in Japanese type 2
diabetes: The association between remaining
b-cell function and the achievement of the
HbA1c target 1 year after initiation
We would like to thank Wilbrink et al.1
for their interest and comments on our
recent article regarding the glycated
hemoglobin (HbA1c)-lowering effect of
glucagon-like peptide-1 receptor agonist
liraglutide with basal insulin among
Japanese individuals with type 2
diabetes.
We have reported that the HbA1c-
lowering effects of liraglutide/basal insu-
lin combination rely on remaining b-cell
function, and that the cut-off value of
the C-peptide immunoreactivity index, a
b-cell function-related index frequently
used in Japanese clinical settings, is 1.103
for the achievement of HbA1c < 7.0% at
54 weeks after initiating the liraglutide/
basal insulin combination2. In our study,
we found that changes in HbA1c were
not affected by type 2 diabetes duration,
unlike the Wilbrink et al. study (Fig-
ure 1b). This discrepancy might be due
to several reasons. First, we studied
patients receiving liraglutide/basal insulin
combination in replacement of multiple
daily injection insulin therapy or basal
insulin-supported oral therapy, whereas
Wilbrink et al. studied those receiving
liraglutide in replacement of insulin ther-
apy. We previously showed that discon-
tinuation of liraglutide as a result of
hyperglycemia after switching from insu-
lin is affected by remaining b-cell func-
tion and type 2 diabetes duration3. In
addition, we also reported that the
HbA1c-lowering effects of liraglutide
monotherapy and sulfonylurea combina-
tion rely on remaining b-cell function
and type 2 diabetes duration (Figure 1a)
in a study in which 74% of the study
patients had been taking insulin before
initiating liraglutide4. Importantly, the C-
peptide immunoreactivity index cut-off
value for HbA1c < 7.0% achievement by
liraglutide monotherapy and sulfonylurea
combination was higher than that of
liraglutide/basal combination (1.86 and
1.10, respectively)2,4. It is widely accepted
that b-cell function progressively declines
over time in type 2 diabetes patients,
making it difﬁcult to obtain appropriate
glycemic control without insulin use5,6. It
is possible that basal insulin co-adminis-
tration compensated for the decline in
b-cell function associated with longer
type 2 diabetes duration in our study2.
Indeed, it was shown that the addition
of basal insulin signiﬁcantly improved
HbA1c in individuals inadequately con-
trolled by liraglutide7. Second, the dis-
crepancy between our study and the
Wilbrink et al. study might be due to
ethnic difference in type 2 diabetes
pathophysiology. Type 2 diabetes in East
Asian patients is characterized primarily
by non-obesity and b-cell dysfunction,
unlike type 2 diabetes in Caucasian
patients, which is characterized by obe-
sity and insulin resistance8. As impaired
b-cell function is observed even in the
early stage of type 2 diabetes in East
Asian patients, type 2 diabetes duration
might have less signiﬁcance in predicting
the HbA1c-lowering effects of liraglutide.
Third, the discrepancy might be due to
limited sample size (the Usui study on
liraglutide/basal insulin, n = 38; the Usui
study on liraglutide monotherapy or sul-
fonylurea combination, n = 88; and the
Wilbrink et al. study, n = 69). Depen-
dence of HbA1c-lowering effects of
liraglutide/basal insulin combination on
type 2 diabetes duration awaits further
investigation by studies with larger sam-
ple sizes. Nevertheless, it is conceivable
that liraglutide exerts greater HbA1c-low-
ering effects in the early stage of type 2
diabetes when ample b-cell function
remains, and that addition of basal insu-
lin or other antidiabetic drugs is required
when b-cell function becomes substan-
tially reduced.
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Figure 1 | Changes of glycated hemoglobin (HbA1c) in Japanese patients with type 2 diabetes
receiving (a) liraglutide monotherapy or sulfonylureas (SU) combination and (b) liraglutide/basal
insulin combination. The patients were subdivided into two groups by medians of type 2
diabetes duration: (a) 10 years and (b) 16 years. Blue, those with type 2 diabetes duration below
the median: (a) n = 37 and (b) n = 18); and red, those with type 2 diabetes duration with the
median or above: (a) n = 51 and (b) n = 19). Time-course curves were analyzed by mixed-
effects models including group, time, and the interaction of group and time, and the P-values
are shown. #P < 0.05 (vs patients with the median or above) by the Mann–Whitney U-test. The
statistical analysis was carried out using SPSS Statistics 24 software (IBM Corp., Armonk, New York,
USA). Each value represents the mean – standard error of the mean.
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